Experimental treatments for hypoxic ischaemic encephalopathy

Area of Science:

• Neonatal neurology
• Perinatal medicine
• Neurocritical care

Background:

• Hypoxic ischemic encephalopathy (HIE) is a major cause of infant death and disability globally.
• Therapeutic hypothermia (cooling) is now a clinical reality for HIE, demonstrating significant benefits.
• Despite its efficacy, approximately 50% of infants treated with hypothermia still experience adverse outcomes.

Purpose of the Study:

• To review current neuroprotective strategies for HIE, focusing on therapeutic hypothermia.
• To explore novel therapeutic agents that may enhance hypothermia's effectiveness.
• To discuss the role of biomarkers and future regenerative therapies for HIE.

Main Methods:

• Review of recent experimental data and clinical trials on therapeutic hypothermia for HIE.
• Discussion of adjunctive neuroprotective agents including inhaled xenon, N-acetylcysteine, melatonin, erythropoietin, and anticonvulsants.
• Exploration of biomarkers, specifically cerebral magnetic resonance spectroscopy (MRS) lactate/N-acetyl aspartate (NAA) ratios, for early prognostication.

Main Results:

• Therapeutic hypothermia reduces death and neurological impairment in HIE infants (NNT ~9).
• Experimental data suggest additive or synergistic neuroprotection when combining hypothermia with other agents.
• Cerebral MRS lactate/NAA ratios show promise for early prognostic information.

Conclusions:

• While therapeutic hypothermia is beneficial for HIE, further neuroprotection is needed.
• Investigating combination therapies and novel agents like xenon, melatonin, and erythropoietin is crucial.
• Biomarkers and future regenerative approaches hold potential for improving HIE outcomes.